more conservative dosing for renal patients using erythropoiesis-stimulating agents

August 2011

You'll see more conservative dosing for renal patients using erythropoiesis-stimulating agents...Procrit, Epogen, Aranesp.

FDA no longer recommends targeting a specific hemoglobin concentration for these drugs in chronic kidney disease patients.

There's not an additional benefit to aiming for a hemoglobin over 11 g/dL...and it increases the risk of heart attack, stroke, and death.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote